Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regulus Therapeutics
(NQ:
RGLS
)
1.580
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regulus Therapeutics
< Previous
1
2
3
4
5
Next >
Regulus Therapeutics's Earnings: A Preview
March 09, 2022
Regulus Therapeutics (NASDAQ:RGLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 02, 2022
Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a...
Via
Benzinga
Earnings Scheduled For August 10, 2021
August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
68 Biggest Movers From Yesterday
March 03, 2022
Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to...
Via
Benzinga
Executives Buy Over $6M Of 5 Penny Stocks
February 08, 2022
Although gold prices traded slightly lower to below $1,820 an ounce on Tuesday ahead of US inflation data due later in the week, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 04, 2022
Gainers Calyxt (NASDAQ:CLXT) shares rose 12.4% to $1.63 during Friday's pre-market session. The company's market cap stands at $62.7 million. Better Therapeutics (...
Via
Benzinga
5 Penny Stocks Insiders Are Buying: OpGen, Regulus Therapeutics And More
January 27, 2022
The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above marke...
Via
Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
January 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...
Via
Benzinga
Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder
January 21, 2022
Regulus Therapeutics Inc (NASDAQ: RGLS) has completed a pre-investigational new drug (Pre-IND) meeting with the FDA to obtain input on the Company's RGLS8429...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
January 12, 2022
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...
Via
Benzinga
How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More
October 18, 2021
Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward. What To Watch...
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher
October 13, 2021
Toward the end of trading Wednesday, the Dow traded up 0.06% to 34,398.86 while the NASDAQ rose 0.70% to 14,566.72. The S&P also rose, gaining 0.31% to 4,364.35. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stocks Hitting New 52-Week Lows Today
January 03, 2022
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 13, 2021
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The market value of their outstanding shares is at $87....
Via
Benzinga
Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge
October 13, 2021
Midway through trading Wednesday, the Dow traded down 0.43% to 34,229.72 while the NASDAQ rose 0.40% to 14,524.02. The S&P also fell, dropping 0.10% to 4,346.21. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
50 Biggest Movers From Yesterday
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
October 13, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 13, 2021
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...
Via
Benzinga
Exposures
Product Safety
20 Stocks Moving in Wednesday's Pre-Market Session
October 13, 2021
Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
September 02, 2021
Upgrades For Okta Inc (NASDAQ:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 17, 2021
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9...
Via
Benzinga
Recap: Regulus Therapeutics Q2 Earnings
August 10, 2021
Shares of Regulus Therapeutics (NASDAQ:RGLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 65.22% year...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
August 06, 2021
Gainers Nuwellis (NASDAQ:NUWE) shares in...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 15, 2021
Gainers Alterity Therapeutics (NASDAQ:ATHE) shares rose 13.66% to $1.58 during Thursday's pre-market session. The market value of their outstanding shares is at $63.3...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
July 08, 2021
Gainers Dare Bioscience (NASDAQ:DARE) sto...
Via
Benzinga
Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program
June 25, 2021
Regulus Therapeutics Inc (NASDAQ: RGLS) announced the presentation of additional data from the first cohort from Phase 1b trial of RGLS4326 for autosomal dominant...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.